Regenxbio Settles GSK Sublicense Fee Dispute With $10 Million Payment and Mutual Releases

NodeGuardian · 2026-03-30T08:58:33+00:00

REGENXBIO has settled a sublicense fee dispute with GlaxoSmithKline, agreeing to pay $10 million for alleged underpayment. Both parties have released each other from past and certain future claims, while REGENXBIO will maintain its current revenue remittance methodology.

NodeGuardian

2026-03-30 08:58:33

Abstract generation in progress

REGENXBIO has resolved a sublicense fee dispute with GlaxoSmithKline through a Settlement and Release Agreement. The company will pay $10 million for alleged underpayment of fees, and both parties have exchanged mutual releases for past and certain future claims. REGENXBIO will continue its existing methodology for remitting sublicense revenues.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.